336 related articles for article (PubMed ID: 34470561)
1. Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part I. a literature review.
Dexter E; Kong Q
Expert Rev Neurother; 2021 Sep; 21(9):969-982. PubMed ID: 34470561
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development.
Dexter E; Kong Q
Expert Rev Neurother; 2021 Sep; 21(9):983-991. PubMed ID: 34470554
[No Abstract] [Full Text] [Related]
3. Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases.
Iraci N; Stincardini C; Barreca ML; Biasini E
Virus Res; 2015 Sep; 207():62-8. PubMed ID: 25456402
[TBL] [Abstract][Full Text] [Related]
4. Roles of endoproteolytic α-cleavage and shedding of the prion protein in neurodegeneration.
Altmeppen HC; Prox J; Puig B; Dohler F; Falker C; Krasemann S; Glatzel M
FEBS J; 2013 Sep; 280(18):4338-47. PubMed ID: 23413979
[TBL] [Abstract][Full Text] [Related]
5. Prion Protein: The Molecule of Many Forms and Faces.
Kovač V; Čurin Šerbec V
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163156
[TBL] [Abstract][Full Text] [Related]
6. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
7. Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrP
Corda E; Du X; Shim SY; Klein AN; Siltberg-Liberles J; Gilch S
Mol Neurobiol; 2018 Oct; 55(10):7758-7774. PubMed ID: 29460268
[TBL] [Abstract][Full Text] [Related]
8. Shedding light on prion disease.
Glatzel M; Linsenmeier L; Dohler F; Krasemann S; Puig B; Altmeppen HC
Prion; 2015; 9(4):244-56. PubMed ID: 26186508
[TBL] [Abstract][Full Text] [Related]
9. α-Cleavage of cellular prion protein.
Liang J; Kong Q
Prion; 2012; 6(5):453-60. PubMed ID: 23052041
[TBL] [Abstract][Full Text] [Related]
10. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
11. Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation.
Mohammadi B; Linsenmeier L; Shafiq M; Puig B; Galliciotti G; Giudici C; Willem M; Eden T; Koch-Nolte F; Lin YH; Tatzelt J; Glatzel M; Altmeppen HC
Mol Neurobiol; 2020 Jun; 57(6):2812-2829. PubMed ID: 32367491
[TBL] [Abstract][Full Text] [Related]
12. An optimized Western blot assay provides a comprehensive assessment of the physiological endoproteolytic processing of the prion protein.
Vanni I; Iacobone F; D'Agostino C; Giovannelli M; Pirisinu L; Altmeppen HC; Castilla J; Torres JM; Agrimi U; Nonno R
J Biol Chem; 2023 Feb; 299(2):102823. PubMed ID: 36565989
[TBL] [Abstract][Full Text] [Related]
13. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.
Resenberger UK; Harmeier A; Woerner AC; Goodman JL; Müller V; Krishnan R; Vabulas RM; Kretzschmar HA; Lindquist S; Hartl FU; Multhaup G; Winklhofer KF; Tatzelt J
EMBO J; 2011 May; 30(10):2057-70. PubMed ID: 21441896
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal domain of the prion protein is required and sufficient for liquid-liquid phase separation: A crucial role of the Aβ-binding domain.
Kamps J; Lin YH; Oliva R; Bader V; Winter R; Winklhofer KF; Tatzelt J
J Biol Chem; 2021 Jul; 297(1):100860. PubMed ID: 34102212
[TBL] [Abstract][Full Text] [Related]
15. Increased prion protein processing and expression of metabotropic glutamate receptor 1 in a mouse model of Alzheimer's disease.
Ostapchenko VG; Beraldo FH; Guimarães AL; Mishra S; Guzman M; Fan J; Martins VR; Prado VF; Prado MA
J Neurochem; 2013 Nov; 127(3):415-25. PubMed ID: 23651058
[TBL] [Abstract][Full Text] [Related]
16. Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases.
Béland M; Roucou X
Prion; 2014; 8(1):106-10. PubMed ID: 24335160
[TBL] [Abstract][Full Text] [Related]
17. A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein.
Massignan T; Cimini S; Stincardini C; Cerovic M; Vanni I; Elezgarai SR; Moreno J; Stravalaci M; Negro A; Sangiovanni V; Restelli E; Riccardi G; Gobbi M; Castilla J; Borsello T; Nonno R; Biasini E
Sci Rep; 2016 Mar; 6():23180. PubMed ID: 26976106
[TBL] [Abstract][Full Text] [Related]
18. Separate mechanisms act concurrently to shed and release the prion protein from the cell.
Wik L; Klingeborn M; Willander H; Linne T
Prion; 2012; 6(5):498-509. PubMed ID: 23093798
[TBL] [Abstract][Full Text] [Related]
19. Novel regulators of PrP
Colini Baldeschi A; Vanni S; Zattoni M; Legname G
Expert Opin Ther Targets; 2020 Aug; 24(8):759-776. PubMed ID: 32631090
[TBL] [Abstract][Full Text] [Related]
20. Prion protein "gamma-cleavage": characterizing a novel endoproteolytic processing event.
Lewis V; Johanssen VA; Crouch PJ; Klug GM; Hooper NM; Collins SJ
Cell Mol Life Sci; 2016 Feb; 73(3):667-83. PubMed ID: 26298290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
